{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(6)"],"submitter":["Zapatero-Solana E"],"pubmed_abstract":["Background
CDK4/6 inhibitors (CDK4/6i) combined with hormone therapies have demonstrated clinical benefit in HR+, HER2- breast cancer patients. However, the onset of resistance remains a concern and highlights a need for therapeutic strategies to improve outcomes. The objective of this study was to develop an in vitro model to better understand the mechanisms of resistance to CDK4/6i + hormone therapies and identify therapeutic strategies with potential to overcome this resistance.Methods
The HR+, HER2- T47D breast cancer cell line genetically modified with a Geminin-Venus reporter construct was treated with CDK4/6i (abemaciclib or palbociclib) in combination with 4-hydroxytamoxifen (tamoxifen). Resistant cells were identified by cell sorting for Geminin (%GEM+), a marker o"],"journal":["International journal of molecular sciences"],"pagination":["2643"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11942273"],"repository":["biostudies-literature"],"pubmed_title":["Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing."],"pmcid":["PMC11942273"],"pubmed_authors":["Ding Y","Pulliam N","Lallena MJ","de Dios A","Zapatero-Solana E","Ortiz-Ruiz MJ"],"additional_accession":[]},"is_claimable":false,"name":"Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.","description":"Background
CDK4/6 inhibitors (CDK4/6i) combined with hormone therapies have demonstrated clinical benefit in HR+, HER2- breast cancer patients. However, the onset of resistance remains a concern and highlights a need for therapeutic strategies to improve outcomes. The objective of this study was to develop an in vitro model to better understand the mechanisms of resistance to CDK4/6i + hormone therapies and identify therapeutic strategies with potential to overcome this resistance.Methods
The HR+, HER2- T47D breast cancer cell line genetically modified with a Geminin-Venus reporter construct was treated with CDK4/6i (abemaciclib or palbociclib) in combination with 4-hydroxytamoxifen (tamoxifen). Resistant cells were identified by cell sorting for Geminin (%GEM+), a marker o","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-05-23T03:22:46.619Z","creation":"2025-07-02T03:04:39.42Z"},"accession":"S-EPMC11942273","cross_references":{"pubmed":["40141282"],"doi":["10.3390/ijms26062643"]}}